期刊文献+

米非司酮调控乳腺癌细胞增殖的研究 被引量:3

Effect of mifepristone on the proliferation of human breast cancer cell line MCF-7and T47D in vitro
下载PDF
导出
摘要 目的研究米非司酮对乳腺癌细胞系MCF-7和T47D的增殖抑制作用。方法采用四甲基偶氮唑盐(MTT)法检测米非司酮对乳腺癌细胞系MCF-7和T47D的半数抑制浓度(IC50)。不同浓度米非司酮(0.25、2.5、25和50μmol/L)分别处理人乳腺癌细胞系MCF-7和T47D1、2、3d后,观察细胞形态变化,以及检测各组细胞生长曲线。结果米非司酮对乳腺癌MCF-7和T47D细胞均有抑制作用,其抑制率均随着米非司酮浓度的增加而变化,存在明显的量效关系。通过对两种细胞抑制率(IR)值直线回归分析,米非司酮对MCF-7细胞的IC50为51.21μmol/L,对T47D细胞的IC50为54.29μmol/L。形态学观察发现,各组细胞体积变小,细胞间的链接消失,细胞内明显有黑色小颗粒聚集。25和50μmol/L浓度米非司酮对MCF-7乳腺癌细胞株生长抑制作用明显,特别是50μmol/L干预24h后在高倍镜下可见明显的核质浓缩。结论米非司酮对病理分型、激素受体型不同的乳腺癌MCF-7和T47D细胞均具有抑制增殖的作用,并呈时间和剂量依赖效应。 Objective. To explore the effect of mifepristone on proliferation of human breast cancer cells MCF-7 and T47D in vitro. Methods. MCF-7 and T47D cells were treated by different concentrations(0. 25,2.5,25 and 50 μmol/L)of mifepristone. Then the growth inhibitions of mifepristone were examined by MTT assay on day 1,2,3 to median effective inhibitory concentration 50% (IC50)and growth curves. The cell morphology changes were also observed. Results: Mifepristone had inhibiting effects on both MCF-7 and T47D cells,of which the inhibiting effects were dependent on the concentration. The IC50 was 51.21 μmol/L in MCF-7 cells and 54.29 /lmol/L in T47D cells respectively,which was revealed by linear regression of IR values. Cell morphology observation found that cell volume became smaller, cell-cell connection disappeared and small black granules were clustered in both cells. The inhibiting effects in high concentrations(25 and, 50 μmol/L)were stronger than those of low concentrations (0.25 and 2.5 μmol/L)on both cancer cells. Of note, clear concentrated karyoplasms were observed 24 hours after 50μmol/L mifepristone treatment in both cells. Conclusions: Mifepristone inhibits the proliferation of both MCF-7 and T47D cells in a dose-dependent manner.
出处 《生殖医学杂志》 CAS 2014年第4期306-311,共6页 Journal of Reproductive Medicine
基金 北京市自然科学基金资助项目(7132160) 中央级公益性科研院所基本科研专项基金(2010GJSSJKA04)
关键词 米非司酮 乳腺癌 细胞增殖 半数抑制浓度 Mifepristone Breast cancer cell Proliferation Half maximal inhibitory concentration
  • 相关文献

参考文献13

  • 1Chlebowski RT, Kim JS, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings [J]. Cancer Prey Res(Phila), 2014, [Epub ahead of print].
  • 2Yip CH, Smith RA, Anderson BO, et al. Guideline implementation for breast healthcare in low and middle- income countries: early detection resource allocation [J]. Cancer,g008,113(8 supple) :2244-2256.
  • 3Ziller V, Kalder M, Albert US, et al. Adberence to adiuvant endocrine therapy in postmenopausal women with breast cancer [J]. Ann Oncol, 2009,20 :431-436.
  • 4Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention [J]. Cancer Prey Res(Phila) ,2011,4:1360-1365.
  • 5裴开颜,肖碧莲.每周一次口服米非司酮用于避孕的机理研究[J].生殖医学杂志,2008,17(1):6-10. 被引量:6
  • 6Murphy AA, Kettel LM, Morales AJ. et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486 [J].J Clin Endoerinol Metab,1993,76:513 -517.
  • 7Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry [J]. Expert Opin Pharmacother, 2008, 9: 2487-2496.
  • 8Ramondetta LM,Johnson AJ,Sun CC,et al. Phase 2 trial of mifepristone(RU-486) in advanced or recurrent endometrioid adenocarcinoma or tow-grade endometrial stromal sarcoma [J]. Cancer, 2009,115 : 1867-1874.
  • 9Roeereto TF, Brady WE, Shahin MS, et al.A phaseⅡ evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study [ J]. Gynecol Oncol,2010,116 : 332-334.
  • 10Chabbert-Buffet N, Ouzounian S, Kairis AP, etal. Contraceptive applications of progesterone receptor modulators [J]. Eur J Contracept Reprod Health Care, 2008, 13:222-230.

二级参考文献5

共引文献5

同被引文献41

  • 1郑延梅,牛瑞宇,姜华.米非司酮配伍米索前列醇抗早孕的临床观察与处理[J].中国实用医刊,2010,37(19):94-95. 被引量:2
  • 2邹艳芳.米非司酮配伍米索前列醇用于催经止孕的临床研究[J].中国医药,2007,2(2):119-120. 被引量:5
  • 3Ryan IP,Schriock ED,Taylor RN.Isolation,characterization,and comparison of human endometrial and endometriosis cells in vitro[J]. J Clin Endocrinol Metab,1994,78:642-649.
  • 4Matthews CJ,Redfern CP,Hirst BH,et al.Characterization of human purified epithelial and stromal cells from endometrium and endometriosis in tissue culture[J]. Fertil Steril,1992,57:990-997.
  • 5Schaff EA.Mifepristone:ten years later[J]. Contraception,2010,81:1-7.
  • 6Sarkar NN.The potential of mifepristone(RU-486)as an emergency contraceptive drug[J]. Acta Obstet Gynecol Scand,2005,84:309-316.
  • 7Freeburg EM,Goyeneche AA,Telleria CM.Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment[J]. Int J Oncol,2009,34:743-755.
  • 8Prange-Kiel J,Rune GM,Wallwiener D,et al.Inhibition of proliferation and differentiation by RU486 in human endometrial stromal and epithelial cells in vitro[J]. Exp Clin Endocrinol Diabetes,2000,108:275-281.
  • 9Greb RR,Kiesel L,Selbmann AK,et al.Disparate actions of mifepristone(RU486)on glands and stroma in the primate endometrium[J]. Hum Reprod,1999,14:198-206.
  • 10Hull ML,Nisenblat V.Tissue and circulating microRNA influence reproductive function in endometrial disease[J]. Reprod Biomed Online,2013,27:515-529.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部